Drugs / NBE-002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04441099 | Jun 2020 → Aug 2023 | triple-negative breast carcinoma | NBE-Therapeutics AG | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NBE-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04441099 ↗ |
| Route | Intravenous | “NBE-002 will be given intravenously on Day 1 of repeated 28-day cycles.” NCT04441099 ↗ |
| Target | ROR1 | “anti-ROR1 antibody-drug conjugate” NCT04441099 ↗ |